| |
Baseline
|
2 weeks
|
4 weeks
|
8 weeks
|
1 year
|
|---|
|
Group 1
| |
N = 93
|
N = 93
|
N = 93
|
N = 93
|
N = 93
|
|
GAS scores
|
8.74 ± 2.99
|
8.79 ± 2.90
|
8.46 ± 3.07
|
6.79 ± 2.27**
|
5.89 ± 2.11**
|
|
Deterioration (n, %)
| |
7/93 (7.52%)
|
11/93 (11.8%)
|
10/93 (10.8%)
|
8/93 (8.6%)
|
|
Improvement (n, %)
| |
9/93 (9.6%)
|
37/93 (39.8%)
|
64/93 (68.8%)
|
82/93 (88.2%)
|
|
Barthel scores
|
54.52 ± 14.20
|
55.01 ± 14.71
|
56.99 ± 15.34
|
66.51 ± 15.51**
|
74.68 ± 16.15**
|
|
Group 2
| |
N = 65
|
N = 65
|
N = 65
|
N = 59
|
N = 59
|
|
GAS scores
|
8.40 ± 3.49
|
8.69 ± 3.44
|
9.20 ± 3.89*
|
8.17 ± 3.57
|
7.89 ± 3.76
|
|
Deterioration (n, %)
| |
13/65 (20%)
|
22/65 (33.8%)
|
21/65 (32.3%)
|
17/65 (26.2%)
|
|
Improvement (n, %)
| |
8/65 (12.30%)
|
19/65 (29.2%)
|
30/65 (46.1%)
|
37/65 (58.5%)
|
|
Barthel scores
|
58.38 ± 18.65
|
57.08 ± 17.92
|
53.23 ± 19.27
|
61.52 ± 18.67
|
64.57 ± 21.27
|
- Group 1: treated by sodium 2, 3-dimercapto-1-propane sulfonate in combination of zinc; Group 2: treated by D-penicillamine; Global Assessment Scale, GAS Compared with baseline, *P < 0.05, **P < 0.01
